Global Liquid Biopsy Market, 2018: Companies are Vying for a Higher Market Position in the Early Cancer Screening Market

News provided by

Oct 25, 2018, 18:30 ET

DUBLIN, Oct. 25, 2018 /PRNewswire/ --

The "Growth Opportunities in the Global Liquid Biopsy Market, 2018" report has been added to ResearchAndMarkets.com's offering.

Liquid biopsy (CTCs and ctDNAs) is slowly gaining momentum in clinical care given its advantages over the traditional tissue-based gold standard methods. Short-term applications in cancer care range from risk assessment to cancer recurrence monitoring. Despite the proven advantages, there is still a significant number of barriers to adoption such as high cost of next-generation sequencing (NGS), reimbursement scenario and the establishment of clinical utility of mutation and clinical evidence.

Liquid biopsy remains an interesting business opportunity for several investors and the quest for the most successful company continues. With GRAIL announcing over $1.3 billion in financing, the modality has also garnered interest from several pharma companies vying to capture their share of the market by co-developing drugs and diagnostic products. CTCs and ctDNAs have extended applications across oncology, NIPT (non-invasive prenatal testing), transplant diagnostics and infectious diseases. This report provides a strategic insight into liquid biopsy test makers relating to the challenges they will encounter and lists some of the winning strategies to gain reimbursement and market access. It also highlights growth opportunities where companies can gain the first-mover advantage, and provides a guidance for investment bankers on the most successful and unique disruptive technology.

It is important to identify winning strategies in order to be successful. Given the tricky nature of this market, establishing clinical utility and clinical evidence and getting the test into guidelines are some of the key pathways for success. This report discusses regional challenges, regulatory barriers in the UK, China and the US. Key drivers would include the following: Identifying the area of unmet need; aiming for incorporating the test within guidelines and screening programs; overcoming regulatory and reimbursement barriers; and innovating to draw maximum capital from investors.

Broadly three types of companies form the competitive landscape in this market - liquid biopsy kit providers, liquid biopsy instrument providers. Most activity is sensed within "liquid biopsy as a service model".

Currently, there are no clear guidelines that provide a definitive regulatory/reimbursement roadmap in emerging countries such as India where the concept is still in its nascent stages.

Top market trends include:

Increasing interest from pharma companies forging partnerships with diagnostic test developers to advance their drug discovery and development activities.
Companies are leaning towards biomarkers that are listed in the NCCN guidelines as a low-risk approach and which offer more guaranteed reimbursement.
Biomarker tests are focusing on multi-gene or multi-cancer testing rather than a single gene approach.
Companies are pushing the boundaries beyond oncology testing.

Key Topics Covered:

1. EXECUTIVE DASHBOARD

Purpose of this Experiential Study
5 Step Process to Transformational Growth
Scope and Segmentation
Market Highlights
Strategic Imperatives for Suppliers and Laboratories
Growth Themes for the Liquid Biopsy Market
Key Questions this Study will Answer
Top 3 Predictions

2. MARKET OVERVIEW

What is Liquid Biopsy?
Overview of Liquid Biopsy Techniques and Biomarkers
Liquid Biopsy - Where are the Growth Opportunities?
Tapping into Oncology-specific Opportunities
Deeper Look Into Biopsies
Key Stakeholders (Full Adoption of Liquid Biopsy)
Clinical Trials in Liquid Biopsy
Market Landscape - Pharmaceutical Investments
Market Drivers
Market Restraints
Commercialized Tests (US)
Impact of NCD on Liquid Biopsy Testing
Notable Market Activities
Market Landscape - Investments

3. COMPETITOR LANDSCAPE

Overall Competitive Landscape - Types of Companies
Overview of Competitive Landscape - Service Providers
Top 3 Trends and Vendor Strategies
Key Focus Areas of Liquid Biopsy Companies
Liquid Biopsy Service Provider - Competitor Analysis Snapshot
Investments and Technology - By Company
Investments - By Technology
Biomarker and Technology Choice Analysis
Competitor Matrix - Product Type

4. REGIONAL ANALYSIS

Predictions on Adoption of Liquid Biopsy Across Geographies
Analysis - US
Analysis - Europe/UK
Analysis - China
Analysis - India

5. GROWTH STRATEGY

Growth Opportunities
Growth Opportunity 1 - Tool to Predict Response to Therapy
Growth Opportunity 2 - Prognosis and Early Detection for Cancer
Growth Opportunity 3 - Moving Beyond Routine Cancers
Growth Opportunity 4 - Technology Advancements
2018 Liquid Biopsy Market Participant Strategies
Winning Strategies - Recommended Growth Strategies
Importance of Clinical Validation and Clinical Utility and Path to Reimbursement
GRAIL - Strong Clinical Trial Strategy and Technology Superiority Using AI/ML
Guardant Health - Established Presence in Recurrence Monitoring
Freenome - Early-stage Company Focusing on Machine Learning Technology
Biocept
Natera - Building on the NIPT Expertise
Companies to Action (C2A Summary)
Path to Reimbursement/Coverage

6. THE LAST WORD

Key Conclusions and Future Outlook
Acronyms

7. APPENDIX (CAPITAL PRICING AND INSTALLED BASE)

List of Companies Mentioned in the Report
List of Exhibits

Companies Mentioned

Biocept
Natera
GRAIL
Guardant Health
Freenome

For more information about this report visit https://www.researchandmarkets.com/research/pz72l3/global_liquid?w=5

Did you know that we also offer Custom Research? Visit our Custom Research page to learn more and schedule a meeting with our Custom Research Manager.

Media Contact:

Research and Markets
Laura Wood, Senior Manager
[email protected]

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

SOURCE Research and Markets